SynthesisEpidemiology and infection2017
Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions.
Synthesis in Epidemiology and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Hepatitis C distribution across diverse population groups in the Eastern Mediterranean Region: An umbrella review.PloS one · 2026Pooled it
- Characterization of the hepatitis C virus epidemic in Pakistan.BMC infectious diseases · 2019Pooled it
- The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses.Scientific reports · 2019Pooled it
- Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis.Ethiopian journal of health sciences · 2019Pooled it
- Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.PloS one · 2017Pooled it
- The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis.Medicina (Kaunas, Lithuania) · 2025Trial
- Genetic variants underlying precancerous conditions of hepatocellular carcinoma.International journal of cancer · 2026Review
- Hepatitis C virus among hemodialysis patients: burden, risks, and prevention in resource-limited regions.International urology and nephrology · 2025Observational
- Prevalence of hepatitis C virus infection in Qatar's resident population based on a national screening campaign.Scientific reports · 2025Article
- Hepatitis C virus transmission among people who inject drugs in the Middle East and North Africa: mathematical modeling analyses of incidence and intervention impact.EClinicalMedicine · 2025Article
- Prevalence of occult hepatitis C virus infection (OCI) among hemodialysis patients; a cross-sectional study from Lorestan Province, Western Iran.Virusdisease · 2024Article
- Article
- The Seroprevalence of Hepatitis C Virus (HCV) in Hemodialysis Patients in Oman: A National Cross-Sectional Study.Journal of epidemiology and global health · 2023Article
- Article
- Patterns and trends of hepatitis C virus infection in Jordan: an observational study.Frontiers in public health · 2023Observational
- Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.Viruses · 2022Review
- Molecular characterization and genotyping of hepatitis C virus from Sudanese end-stage renal disease patients on haemodialysis.BMC infectious diseases · 2022Article
- Occult hepatitis C virus infection in the Middle East and Eastern Mediterranean countries: A systematic review and meta-analysis.World journal of hepatology · 2021Article
- Prevalence and Risk Factors Associated with Hepatitis B and Hepatitis C Infections among Patients Undergoing Hemodialysis: A Single-Centre Study in Somalia.International journal of nephrology · 2021Article
- Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa.Hepatology communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to investigate hepatitis C virus (HCV) epidemiology among hemodialysis (HD) patients in the Middle East and North Africa (MENA). Our data source was an HCV biological measures database populated through systematic literature searches. Descriptive epidemiologic syntheses, effects meta-analyses and meta-regressions, and genotype analyses were conducted. We analyzed 289 studies, including 106 463 HD patients. HCV incidence ranged between 0 and 100% as seroconversion risk, and between 0 and 14·7 per 1000 person-years as incidence rate. The regional pooled mean estimate was 29·2% (95% CI: 25·6-32·8%) for HCV antibody positive prevalence and 63·0% (95% CI: 55·4-70·3%) for the viremic rate. Region within MENA, country income group, and year of data collection were associated with HCV prevalence; year of data collection adjusted odds ratio was 0·92 (95% CI: 0·90-0·95). Genotype diversity varied across countries with four genotypes documented regionally: genotype 1 (39·3%), genotype 2 (5·7%), genotype 3 (29·6%), and genotype 4 (25·4%). Our findings showed that one-third of HD patients are HCV antibody positive and one-fifth are chronic carriers and can transmit the infection. However, HCV prevalence is declining. In context of growing HD patient population and increasing HCV treatment availability, it is critical to improve standards of infection control in dialysis and expand treatment coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.